[CLINICAL TRIAL OF A NEW VITAMIN B 12 DERIVATIVE, HYDROXOCOBALAMIN, IN NEUROPSYCHIATRIC DISEASES].
D001342:Autonomic Nervous System Diseases; D001463:Barbiturates / Q000633:toxicity*; D035843:Biomedical Research; D001774:Blood Chemical Analysis; D002249:Carbon Monoxide Poisoning; D002561:Cerebrovascular Disorders; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D006879:Hydroxocobalamin; D001523:Mental Disorders; D009437:Neuralgia; D009443:Neuritis; D009462:Neurology; D010600:Pharmacology; D011041:Poisoning; D014805:Vitamin B 12
D001463:Barbiturates; D014805:Vitamin B 12; D006879:Hydroxocobalamin; C032232:barbituric acid
AUTONOMIC DYSFUNCTION; BARBITURATE TOXICOLOGY; BLOOD CHEMICAL ANALYSIS; CARBON MONOXIDE POISONING; CEREBROVASCULAR DISORDERS; CHEMISTRY; CLINICAL RESEARCH; HYDROXOCOBALAMIN; MENTAL DISORDERS; NEURALGIA; NEURITIS; NEUROLOGY; PHARMACOLOGY; POISONING